Novavax is a US-based biotechnology company focused on the development of innovative vaccines that leverage our proprietary recombinant nanoparticle technology and aim to prevent various infectious diseases. Our platform has the potential to produce highly immunogenic antigens, enabling the development of vaccines to respond to known and emerging disease threats.